Adam R. Johnson
Department of Inflammation Molecular Sciences
Pfizer Global Research and Development
Ann Arbor
Michigan 48105
USA
Name/email consistency: high
- Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. Johnson, A.R., Pavlovsky, A.G., Ortwine, D.F., Prior, F., Man, C.F., Bornemeier, D.A., Banotai, C.A., Mueller, W.T., McConnell, P., Yan, C., Baragi, V., Lesch, C., Roark, W.H., Wilson, M., Datta, K., Guzman, R., Han, H.K., Dyer, R.D. J. Biol. Chem. (2007)
- Slow-binding inhibition of human prostaglandin endoperoxide synthase-2 with darbufelone, an isoform-selective antiinflammatory di-tert-butyl phenol. Johnson, A.R., Marletta, M.A., Dyer, R.D. Biochemistry (2001)